2016
Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control
Nguyen D, Houillier C, Choquet S, Cassoux N, Soussain C, Le Cossec C, Legarf-Tavernier M, Costopoulos M, LeHoang P, Bodaghi B, Omuro A, Hoang-Xuan K, Touitou V. Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control. Ophthalmology 2016, 123: 2047-2050. PMID: 27137876, DOI: 10.1016/j.ophtha.2016.03.043.Peer-Reviewed Original Research
2015
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio M, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy M, Hoang-Xuan K. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. The Lancet Haematology 2015, 2: e251-e259. PMID: 26688235, DOI: 10.1016/s2352-3026(15)00074-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCytarabineDacarbazineDisease-Free SurvivalFemaleHumansLymphomaMaleMethotrexateMiddle AgedProcarbazineProspective StudiesQuality of LifeTemozolomideTreatment OutcomeVincristineConceptsPrimary CNS lymphomaProgression-free survivalKarnofsky Performance Scale scoreCytarabine groupPhase 2 trialCNS lymphomaPerformance Scale scoreTemozolomide groupElderly populationScale scoreMedian progression-free survivalPhase 2 trial designCommon grade 3Methotrexate-based regimensProphylactic G-CSFMedian overall survivalStandard chemotherapy regimenPoor prognosis patientsQuality of lifeChemotherapy regimenEfficacy endpointPrimary endpointPrognosis patientsElderly patientsImmunocompetent patientsR-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015, 125: 1403-1410. PMID: 25568347, PMCID: PMC4342354, DOI: 10.1182/blood-2014-10-604561.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBusulfanCentral Nervous System NeoplasmsCombined Modality TherapyCyclophosphamideCytarabineFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansLymphoma, Non-HodgkinMaleMethotrexateMiddle AgedNeoplasm GradingNeoplasm StagingProcarbazinePrognosisRituximabSurvival RateThiotepaTransplantation, AutologousVincristineYoung AdultConceptsAutologous stem cell transplantProgression-free survivalHigh-dose chemotherapyPrimary central nervous system lymphomaStem cell transplantOverall survivalR-MPVHigh-dose methotrexate-based chemotherapyTwo-year progression-free survivalConsolidation high-dose chemotherapyMedian progression-free survivalCentral nervous system lymphomaMedian Karnofsky performance status 80Treatment-related deathsTwo-year OSCycles of chemotherapyMethotrexate-based chemotherapyObjective response ratePrimary end pointAcceptable toxicity profileMainstay of treatmentPhase 2 studyPrimary CNS lymphomaNervous system lymphomaBlood-brain barrier
2013
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome
Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal Of Clinical Oncology 2013, 31: 3971-3979. PMID: 24101038, PMCID: PMC5569679, DOI: 10.1200/jco.2013.50.4910.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsChemoradiotherapyCranial IrradiationCytarabineDisease-Free SurvivalFemaleHumansLymphomaMaleMethotrexateMiddle AgedProcarbazineRituximabTimeTreatment OutcomeVincristineConceptsProgression-free survivalMedian progression-free survivalMedian overall survivalPrimary CNS lymphomaOverall survivalR-MPVComplete responseCNS lymphomaMedian Karnofsky performance scoreMulticenter phase II studyLong-term disease controlEnd pointApparent diffusion coefficientExploratory end pointsKarnofsky performance scorePhase II studyPrimary end pointWhole brain radiotherapyLong-term outcomesWhite matter changesHigh response rateInduction chemotherapyStandard WBRTBrain radiotherapyII study
2012
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
Welch MR, Omuro A, DeAngelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro-Oncology 2012, 14: 1304-1311. PMID: 22952196, PMCID: PMC3452344, DOI: 10.1093/neuonc/nos207.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterOlder patientsCancer CenterSurvival rateLower baseline creatinine clearanceMedian progression-free survivalTwo-year survival rateBaseline creatinine clearanceDeep brain involvementSignificant renal toxicityMedian overall survivalPrimary CNS lymphomaProgression-free survivalTertiary care centerHigh-dose MTXPredictors of survivalFifth treatment cycleOcular radiationAggressive therapyCNS lymphomaBrain involvementCreatinine clearanceMost patientsOverall survivalPCNSL patients
2011
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy
Morris PG, Abrey LE, Reiner AS, Wu N, Panageas KS, Seko BS, Deangelis LM, Omuro A. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leukemia & Lymphoma 2011, 52: 1891-1897. PMID: 21699456, DOI: 10.3109/10428194.2011.585527.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCentral Nervous System NeoplasmsCombined Modality TherapyCytarabineFemaleHumansKarnofsky Performance StatusMaleMethotrexateMiddle AgedProcarbazinePrognosisRituximabSurvival AnalysisVincristineConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaProgression-free survivalNervous system lymphomaMTX AUCMethotrexate areaSystem lymphomaMedian Karnofsky performance status (KPS) scoreIntra-patient dose escalationProspective phase II trialKarnofsky performance status scoreLow-dose radiotherapyFirst chemotherapy cyclePerformance status scorePhase II trialImproved tumor controlSubstantial inter-individual variabilityChemotherapy cyclesII trialMTX exposureOverall survivalDose escalationMedian agePrognostic factorsInter-individual variability